RCS - Arecor Therapeutics - Arecor announces AT278 presentation at EASD 2024

Arecor TherapeuticsAnnouncement

03/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240903:nRSC6089Ca&default-theme=true

RNS Number : 6089C  Arecor Therapeutics PLC  03 September 2024

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR ANNOUNCES ORAL PRESENTATION OF POSITIVE AT278 PHASE 1 CLINICAL DATA AT
THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES 2024

 

·    Late-breaking presentation will detail data from Phase I clinical
trial of ultra-concentrated, ultra-rapid acting insulin candidate, AT278, in
overweight and obese people with type 2 diabetes

 

Cambridge, UK, 3 September 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that its abstract titled "Pharmacokinetic and pharmacodynamic properties of highly concentrated insulin aspart AT278 U500 in overweight and obese people with type 2 diabetes" has been selected as a late-breaking oral presentation at the 60(th) Annual Meeting of the European Association for the Study of Diabetes (
EASD (https://www.easd.org/programme-2024.html)
), which will be held from 9-13 September 2024 in Madrid and online.

 

The presentation will take place on Wednesday 11 September during the SO 03 Presentation Session "One size down, three (or more) to go".
 

Oral Presentation:          Pharmacokinetic and pharmacodynamic
properties of highly concentrated insulin aspart AT278 U500 in overweight and
obese people with type 2 diabetes

Presenting Author:        Professor Thomas Pieber, Medical University
of Graz, Austria

Presentation Number:  LBA 53, Station
18

Date and Time:               Wednesday 11 September, 12:45-13:45
(Central European Time)

 

AT278 (500 U/mL) is an ultra-concentrated, ultra-rapid acting, novel
formulation of insulin that accelerates the absorption of insulin post
injection, even when delivered at a high concentration, and hence, a lower
injection volume. With no concentrated (>200 U/mL), rapid acting insulins
on the market, AT278 has potential to be the first, and only, insulin
available to the growing number of patients with high daily insulin
requirements.

 

Sarah Howell, Chief Executive Officer at Arecor, said: "The recent clinical
results from our second Phase I study with AT278 demonstrated superiority
(PK/PD) over NovoRapid® and Humulin® R U-500 in Type 2 diabetics with a high
BMI. This set of data, which builds on positive results from a previous
clinical study in Type 1 diabetic patients, shows that AT278 has the potential
to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin
product enabling miniaturisation of next-generation truly miniaturised,
longer-wear insulin pumps, a key focus for patients, physicians and the
industry. We look forward to Professor Thomas Pieber, Principal Investigator
for the ARE-278-104 clinical trial, sharing the latest data behind this next
generation insulin candidate with scientific colleagues in Madrid."

 

About the EASD

The European Association for the Study of Diabetes (EASD) is a non-profit,
medical scientific association, founded in 1965 to encourage and support
research in the field of diabetes, the rapid diffusion of acquired knowledge
and to facilitate its application. EASD holds its Annual Meeting in a
different European city each year with more than 15,000 delegates from over
130 countries attending. The scientific programme includes more than 1,200
talks and presentations on the latest results in diabetes research by leading
experts in the field.

-ENDS-

 

 

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com (mailto:info@arecor.com)

 Panmure Liberum Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Financial Advisor)
 Nigel Barnes, Satheesh Nadarajah                Tel: +44 (0)203 705 9321

 David Wilson, Claes Spang

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville     Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGZGGLNZGGDZM